In Response: We thank Dr. Ferretti and coworkers for their valuable comments on our article ''High serum levels of matrix metalloproteinase (MMP)-9 and MMP-1 are associated with rapid progression in patients with metastatic melanoma'' (1). Dr. Ferretti is correct in saying that MMP levels can be altered due to cancer therapy and thus their use in the evaluation of disease progression might be difficult. This is evident in patients with breast cancer, in whom the authors have seen transient reduction of serum MMP-2 levels after therapy with zoledronic acid (2) . Zoledronic acid belongs to the group of bisphosphonates (3), of which the important mechanism of action is inhibition of MMPs. Thus, it is possible that drugs of this group might reduce MMP levels and activity in serum and tissue. Other drugs, such as h-IFN, are also known to reduce serum MMP-9 levels (4).
The effect of cytotoxic drugs on MMP levels has not been widely studied and it is therefore difficult to determine whether changes in serum levels of MMPs are due to the effects of chemotherapeutic agents or due to lack of response. In our study, we examined only pretreatment samples and did not repeat the analysis during the therapy cycles. Interestingly, our previous studies with melanoma metastases have shown that tumor tissue MMP-1 levels are associated with favorable chemoimmunotherapy response (5) . It would be interesting to study the expression levels of MMPs in different time points during therapy to see whether any relationship to outcome can be seen.
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